Biomerica Inc
$ 2.30
-0.30%
04 Dec - close price
- Market Cap 7,369,900 USD
- Current Price $ 2.30
- High / Low $ 2.35 / 2.26
- Stock P/E N/A
- Book Value 1.83
- EPS -1.53
- Next Earning Report 2026-01-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.42 %
- ROE -0.70 %
- 52 Week High 8.80
- 52 Week Low 2.08
About
None
Analyst Target Price
$13.00
Quarterly Earnings
| Aug 2025 | May 2025 | Feb 2025 | Nov 2024 | Aug 2024 | May 2024 | Feb 2024 | Nov 2023 | Aug 2023 | May 2023 | Feb 2023 | Nov 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-13 | 2025-08-29 | 2025-04-10 | 2025-01-14 | 2024-10-15 | 2024-08-28 | 2024-04-12 | 2024-01-16 | 2023-10-12 | 2023-08-25 | 2023-04-14 | 2023-01-13 |
| Reported EPS | 0.0008 | -0.73 | -0.0606 | -0.0555 | -0.0782 | -0.0845 | -0.114 | -0.0896 | -0.1065 | -0.11 | -0.12 | -0.12 |
| Estimated EPS | None | 0 | None | None | None | None | None | 0.04 | -0.02 | -0.08 | 0.02 | -0.12 |
| Surprise | 0 | -0.73 | 0 | 0 | 0 | 0 | 0 | -0.1296 | -0.0865 | -0.03 | -0.14 | 0 |
| Surprise Percentage | None% | None% | None% | None% | None% | None% | None% | -324% | -432.5% | -37.5% | -700% | 0% |
Next Quarterly Earnings
| Nov 2025 | |
|---|---|
| Reported Date | 2026-01-13 |
| Fiscal Date Ending | 2025-11-30 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BMRA
2025-10-16 13:36:31
Biomerica, Inc. has announced a marketing services agreement with Henry Schein, Inc. to promote its inFoods Irritable Bowel Syndrome (IBS) test across the United States, excluding New York State. Henry Schein's extensive distribution network will market the inFoods®? IBS test to primary care and Gastroenterology practices. This collaboration aims to accelerate the adoption of this non-pharmaceutical, precision-based diagnostic therapy, supported by a recently published clinical study demonstrating significant reduction in abdominal pain for patients who eliminated identified trigger foods.
2025-10-15 14:07:59
Biomerica, Inc. (BMRA) reported a decrease in its first-quarter revenue to $1.4 million from $1.8 million year-over-year, indicating a challenging financial performance. The company, which specializes in medical diagnostic products, faces profitability issues with negative operating and net margins, and an Altman Z-Score suggesting financial distress. Despite high insider ownership, Biomerica's valuation metrics and low institutional ownership reflect current market challenges and necessitate careful consideration by investors.
2025-10-15 13:37:32
Biomerica Inc. reported a decrease in Q1 revenue due to reduced retail activity. The medical diagnostic firm's stock (BMRA) experienced a slight decline on October 15, 2025, but shows a significant year-to-date gain. The company continues to advance with new product launches and board appointments.
2025-10-15 13:36:55
Biomerica's fiscal Q1 revenue decreased to $1.4 million due to lower retail activity, down from $1.8 million in the prior period. Despite the revenue fall, the company's gross margin improved significantly to 31% from 16%, driven by a higher-margin product mix and reduced operating expenses. Biomerica did not provide specific financial guidance for future periods.
2025-10-15 13:30:00
Biomerica, Inc. announced improved financial results for the first quarter ending August 31, 2025, with a net profit and improved gross margins, despite a decrease in net sales. The company attributed improvements to a higher-margin product mix and reduced operating expenses. Key highlights include regulatory approvals for its Fortel® Ulcer and Kidney Tests in the UAE and the issuance of a Proprietary Laboratory Analysis code for its inFoods® IBS test, aiming to expand market access and enhance diagnostic tools.
2025-10-14 21:13:00
Biomerica Inc. released its Form 10-Q report for Q3 2024, highlighting a significant turnaround to a net income of $0.002 million despite a 24% decrease in net sales to $1.38 million. The company achieved improved gross profit and reduced operational loss through lower contract manufacturing costs and enhanced production efficiency. Future plans include increasing sales, exploring additional financing, and pursuing distribution, partnership, and licensing opportunities for its new products.
